Novotech Releases Comprehensive Report on Oncolytic Virus Therapy
22.1.2025 14:05:00 CET | Business Wire | Press release
Explore the latest insights into global clinical trial trends, innovations, and strategies shaping the future of oncolytic virus therapy.
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics, has released its latest report, Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into this transformative approach to cancer treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122884484/en/
Oncolytic virus therapies utilize genetically modified or naturally occurring viruses to selectively target tumor cells and stimulate immune responses. This dual mechanism is creating new possibilities in oncology and other therapeutic areas.
Key Highlights:
- Global Trial Landscape: Asia-Pacific leads with 40% of OVT clinical trials, followed closely by North America and Europe, reflecting a global focus on advancing these therapies.
- Pipeline Insights: Solid tumors dominate OVT research, with trials targeting cancers such as melanoma, glioblastoma, and pancreatic cancer.
- Innovative Delivery Systems: Advances like nanoparticle systems and cell-based carriers address key challenges in targeting and delivery.
- Combination Therapies: Integration with immune checkpoint inhibitors, CAR-T therapies, and chemotherapy is enhancing the efficacy and scope of OVT.
- Regulatory Overview: Provides guidance on navigating complex global regulatory pathways, including insights into fast-tracking approvals.
This complimentary report offers biotech and pharmaceutical companies, data-driven analysis to navigate the complexities of clinical trials and regulatory frameworks in oncolytic virus therapy.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122884484/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street to Host Investor Day on January 14, 2027, in New York City19.11.2026 15:00:00 CET | Press release
The Company will highlight its opportunities and unique solutions in enterprise software support and its ownership of the Agentic AI ERP market, present its sales strategy and financial model and host a panel discussion featuring Rimini Street global clients from a variety of industries Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced details for its upcoming Investor Day, to be held on January 14, 2027, in New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119878624/en/ Rimini Street to Host Investor Day on January 14, 2027, in New York City Investor Day Details Date: January 14, 2027 Time: 8:30 a.m. – 12:30 p.m. Eastern Time Location: New York City In-Person Attendance: Institutional investors and analysts in
Belkin Named CES Innovation Awards® 2027 Honoree for Titan SmartShield Pro Bright Privacy Screen Protector19.11.2026 15:00:00 CET | Press release
Award-winning screen protection technology redefines mobile privacy with a brighter, clearer viewing experience and improved power efficiency Belkin, a leading consumer electronics brand for over 40 years, today announced that its Titan SmartShield Pro Bright Privacy Screen Protector has been named a CES Innovation Awards® 2027 Honoree in the Mobile Devices, Accessories & Apps category. The recognition celebrates Belkin's innovative approach to screen protection, combining enhanced privacy, optical clarity and durability without compromising the everyday smartphone experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119118768/en/ Belkin Named CES Innovation Awards® 2027 Honoree for Titan SmartShield Pro Bright Privacy Screen Protector The CES Innovation Awards® 2027 program received a record number of submissions – nearly 4,000 – ahead of CES 2027, taking place January 6–9 in Las Vegas. The annual competition, owne
Marsh’s Oliver Wyman to Acquire Financial Services and Technology Consultancy Synpulse19.11.2026 14:08:00 CET | Press release
Oliver Wyman, a global leader in management consulting and a Marsh business (NYSE:MRSH), today announced an agreement to acquire Synpulse, a global technology consulting and AI platform company serving banks, insurers, wealth managers and other financial services organizations. Terms of the deal, expected to close in early 2027, were not disclosed. Banks, insurers and asset managers face significant changes driven by advances in technology, data and AI, as well as evolving business models. As these changes accelerate, clients are looking for partners who can help them navigate every stage of transformation, from strategy to technology implementation and execution. Oliver Wyman and Synpulse have already been working together with combined teams on multiple end-to-end transformations for our clients. The acquisition will enable the two businesses to continue to work closely together, combining complementary capabilities and teams to service clients across strategy, technology and impleme
GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial19.11.2026 14:00:00 CET | Press release
Key milestone in GE HealthCare’s adaptive Phase 2/3 LUMINA clinical trial, with Phase 2 results meeting primary endpoint, showing mangaciclanol and market-leading gadolinium-based agent, gadobutrol, have similar overall diagnostic preference Mangaciclanol was well tolerated in the Phase 2 stage, with no safety concerns identified following its administration Mangaciclanol has received FDA Fast Track designation, recognizing its potential to address significant unmet patient needs; approximately 65 million gadolinium-enhanced MRI procedures are performed each year GE HealthCare to present preliminary Phase 2 results at RSNA 2026 (Industry Expert Theater) GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an
Stronghold Joins the World Economic Forum's New Champions Community19.11.2026 14:00:00 CET | Press release
Stronghold, a fintech infrastructure company, today announced that it has joined the World Economic Forum’s New Champions Community. The New Champions Community is the World Economic Forum’s global network of mission-driven companies, drawn from more than 40 countries and 20 industries. Its work centers on how businesses anticipate change, adapt to disruption and build resilience. Stronghold provides payments infrastructure for merchants and the banks that serve them. The company carries the compliance work that allows banks to serve licensed businesses they would otherwise decline, and makes that work visible to every party in a transaction. That is where resilience gets tested: whether money keeps moving when a market shifts, a rule changes or a bank revisits its risk appetite. “The New Champions Community reflects the values we care about: trust, compliance, and financial innovation,” said Tammy Camp, CEO of Stronghold. “Joining gives us the chance to learn from leaders in industrie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom